LeMaitre Vascular, Inc. (NASDAQ: LMAT) Receives Average “Buy” Analyst Rating



Shares of LeMaitre Vascular, Inc. (NASDAQ: LMAT) received an average “Buy” recommendation from the six brokerages that currently cover the company, reports MarketBeat Ratings. Three analysts rated the stock with a conservation rating and three gave the company a buy rating. The year-over-year average price target among analysts who hedged the stock in the past year is $ 64.25.

LMAT has been the subject of several research analyst reports. Jefferies Financial Group assumed coverage of LeMaitre Vascular in a research note on Thursday, September 16. They set a “buy” rating and a target price of $ 70.00 on the stock. Zacks investment research downgraded LeMaitre Vascular’s stock from a “buy” rating to a “hold” rating in a research note on Tuesday, October 5. Barrington Research raised its target price on LeMaitre Vascular shares from $ 59.00 to $ 64.00 and gave the company an “outperformance” rating in a research note on Friday, July 30. Finally, Roth Capital raised its price target on LeMaitre Vascular shares from $ 55.00 to $ 58.00 and assigned the company a “neutral” rating in a report released on Tuesday, August 3.

LMAT opened at $ 53.49 on Monday. The stock’s fifty-day moving average is $ 55.91 and its 200-day moving average is $ 54.41. LeMaitre Vascular has a one-year minimum of $ 31.21 and a one-year maximum of $ 64.50. The company has a market cap of $ 1.16 billion, a PE ratio of 38.48, a P / E / G ratio of 4.32 and a beta of 1.32. The company has a debt to equity ratio of 0.10, a quick ratio of 2.11 and a current ratio of 4.19.

LeMaitre Vascular (NASDAQ: LMAT) last released its results on Thursday, July 29. The medical device supplier reported earnings per share of $ 0.40 for the quarter, beating the consensus estimate of $ 0.34 by $ 0.06. LeMaitre Vascular had a net margin of 19.12% and a return on equity of 16.51%. The company posted revenue of $ 40.67 million for the quarter, compared to a consensus estimate of $ 40.70 million. On average, equity research analysts predict LeMaitre Vascular will post 1.37 EPS for the current fiscal year.

(A d)

Investors must see this disruptive herbal business before it goes public.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 9. Shareholders of record on Thursday August 26 received a dividend of $ 0.11 per share. The ex-dividend date was Wednesday August 25. This represents an annualized dividend of $ 0.44 and a dividend yield of 0.82%. The distribution rate of LeMaitre Vascular is 42.31%.

A number of hedge funds have recently increased or reduced their holdings in the stock. The Swiss National Bank increased its holdings in LeMaitre Vascular by 1.5% in the first quarter. The Swiss National Bank now owns 39,500 shares of the medical device supplier valued at $ 1,927,000 after acquiring an additional 600 shares in the last quarter. BNP Paribas Arbitrage SA increased its stake in LeMaitre Vascular by 15.6% in the first quarter. BNP Paribas Arbitrage SA now owns 4,069 shares of the medical device supplier valued at $ 198,000 after purchasing 548 additional shares during the last quarter. BlackRock Inc. increased its stake in LeMaitre Vascular by 3.4% in the first quarter. BlackRock Inc. now owns 3,080,512 shares of the medical device supplier valued at $ 150,266,000 after purchasing an additional 101,451 shares during the period. Principal Financial Group Inc. increased its holdings in LeMaitre Vascular by 0.4% during the first quarter. Principal Financial Group Inc. now owns 129,329 shares of the medical device supplier valued at $ 6,309,000 after purchasing an additional 515 shares in the last quarter. Finally, Acadian Asset Management LLC acquired a new stake in shares of LeMaitre Vascular in the 1st quarter valued at approximately $ 231,000. 80.63% of the shares are held by hedge funds and other institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is engaged in the provision of medical devices and human tissue cryopreservation services. The company is focused on the design, marketing, sale, service and technical support of medical devices and implants for the treatment of peripheral vascular diseases. Its products include balloon catheters, carotid shunts, biological patches, radiopaque labeling tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts and motorized phlebectomies.

Read more: Which sectors are represented in the Hang Seng index?

Analyst Recommendations for LeMaitre Vascular (NASDAQ: LMAT)

This instant news alert was powered by narrative science technology and MarketBeat financial data to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in LeMaitre Vascular now?

Before considering LeMaitre Vascular, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold of… and LeMaitre Vascular was not on the list.

While LeMaitre Vascular currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.

See the 5 actions here


Leave A Reply

Your email address will not be published.